Monoamine oxidase inhibitors

25,449views

test

00:00 / 00:00

Monoamine oxidase inhibitors

Family Medicine Rotation

Family Medicine Rotation

Antihistamines for allergies
Glucocorticoids
Coronary artery disease: Clinical
Heart failure: Clinical
Syncope: Clinical
Hypertension: Clinical
Hypercholesterolemia: Clinical
Peripheral vascular disease: Clinical
Leg ulcers: Clinical
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Antiplatelet medications
Hypersensitivity skin reactions: Clinical
Eczematous rashes: Clinical
Papulosquamous skin disorders: Clinical
Alopecia: Clinical
Hypopigmentation skin disorders: Clinical
Benign hyperpigmented skin lesions: Clinical
Skin cancer: Clinical
Diabetes mellitus: Clinical
Hyperthyroidism: Clinical
Hypothyroidism and thyroiditis: Clinical
Dizziness and vertigo: Clinical
Hyperthyroidism medications
Hypothyroidism medications
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Gastroesophageal reflux disease (GERD): Clinical
Peptic ulcers and stomach cancer: Clinical
Diarrhea: Clinical
Malabsorption: Clinical
Colorectal cancer: Clinical
Diverticular disease: Clinical
Anal conditions: Clinical
Cirrhosis: Clinical
Breast cancer: Clinical
Laxatives and cathartics
Antidiarrheals
Acid reducing medications
Anemia: Clinical
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Pneumonia: Clinical
Urinary tract infections: Clinical
Skin and soft tissue infections: Clinical
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anti-mite and louse medications
Chronic kidney disease: Clinical
Kidney stones: Clinical
Urinary incontinence: Pathology review
PDE5 inhibitors
Stroke: Clinical
Lower back pain: Clinical
Headaches: Clinical
Migraine medications
Asthma: Clinical
Chronic obstructive pulmonary disease (COPD): Clinical
Lung cancer: Clinical
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pulmonary corticosteroids and mast cell inhibitors
Joint pain: Clinical
Rheumatoid arthritis: Clinical
Anatomy clinical correlates: Clavicle and shoulder
Anatomy clinical correlates: Arm, elbow and forearm
Anatomy clinical correlates: Wrist and hand
Anatomy clinical correlates: Median, ulnar and radial nerves
Anatomy clinical correlates: Bones, joints and muscles of the back
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid agonists, mixed agonist-antagonists and partial agonists
Antigout medications
Osteoporosis medications
Pregnancy
Routine prenatal care: Clinical
Stages of labor
Breastfeeding
Amenorrhea: Clinical
Contraception: Clinical
Virilization: Clinical
Infertility: Clinical
Vulvovaginitis: Clinical
Sexually transmitted infections: Clinical
Menopause
Abnormal uterine bleeding: Clinical
Cervical cancer: Clinical
Estrogens and antiestrogens
Progestins and antiprogestins
Androgens and antiandrogens
Pediatric allergies: Clinical
Congenital heart defects: Clinical
Pediatric ear, nose, and throat conditions: Clinical
Pediatric constipation: Clinical
Pediatric gastrointestinal bleeding: Clinical
Pediatric vomiting: Clinical
Developmental milestones: Clinical
Puberty and Tanner staging
Precocious and delayed puberty: Clinical
Child abuse: Clinical
Vaccinations: Clinical
Pediatric infectious rashes: Clinical
Pediatric bone and joint infections: Clinical
Pediatric urological conditions: Clinical
Elimination disorders: Clinical
Neurodevelopmental disorders: Clinical
Pediatric ophthalmological conditions: Clinical
Pediatric upper airway conditions: Clinical
Pediatric lower airway conditions: Clinical
BRUE, ALTE, and SIDS: Clinical
Pediatric orthopedic conditions: Clinical
Mood disorders: Clinical
Anxiety disorders: Clinical
Eating disorders: Clinical
Obsessive compulsive disorders: Clinical
Personality disorders: Clinical
Sleep disorders: Clinical
Substance misuse and addiction: Clinical
Somatic symptom disorders: Clinical
Sexual dysfunctions: Clinical
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Tricyclic antidepressants
Monoamine oxidase inhibitors
Atypical antidepressants
Anticonvulsants and anxiolytics: Benzodiazepines
Psychomotor stimulants
Opioid antagonists

Assessments

Flashcards

0 / 9 complete

USMLE® Step 1 questions

0 / 5 complete

USMLE® Step 2 questions

0 / 8 complete

Flashcards

Monoamine oxidase inhibitors

0 of 9 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 5 complete

USMLE® Step 2 style questions USMLE

0 of 8 complete

A 69- year-old woman is brought to the emergency room with her partner after losing consciousness at church. The partner states that there was no seizure-like activity, nausea, and vomiting. She regained consciousness 2 minutes after the syncopal episode. Her medical history includes atypical depression and GERD. Her current medication is a transdermal antidepressant that selectively inhibits MAOb receptors at low doses and is a nonselective MAO inhibitor at higher doses. Family history is noncontributory. She does not consume alcohol or use recreational drugs. She smokes 2-3 packs of cigarettes daily. Her temperature is 38.9°C (102°F), pulse is 110/min, respirations are 20/min, and blood pressure is 90/70 mmHg while standing and 110/70 mm of Hg while lying down. BMI is 20 kg/m2. She is awake, alert, and responds to commands and external stimuli. Pupils are equal and reactive. She moves all her extremities, and +2 reflexes are present throughout. The antidepressant used in this patient is also the agent of choice in the presence of which of the following additional findings on evaluation?

External References

First Aid

2024

2023

2022

2021

Amines

MAO inhibitors p. 593

Anxiety

MAO inhibitors for p. 593

Dopamine p. 241, 332

MAO inhibitor effects p. 593

5-HT

MAO inhibitor effect on p. 593

Hypertensive crisis p. 587

MAO inhibitors as cause p. 593

MAO inhibitors p. 593

atypical depression p. 578

mechanism of p. 593

Parkinson disease p. 563

phobias p. 580

selegiline/rasagiline p. 564

tyramine and p. 243

Norepinephrine (NE)

MAO inhibitor effects p. 593

Serotonin syndrome p. 407, 562, 568, 587

MAO inhibitors p. 593

Transcript

Watch video only

Monoamine oxidase inhibitors, or MAOIs, are a class of medications used in the treatment of depression, which is a mood disorder that causes a persistent feeling of sadness and loss of interest in everyday activities.

Even though the exact cause of depression is still unknown, there is some evidence that suggests it’s related to low levels of serotonin, norepinephrine, and dopamine, which are also called monoamines because they have only one amine group.

Now, monoamine oxidase inhibitors work by increasing levels of serotonin, norepinephrine, and dopamine, which helps to alleviate the symptoms of depression.

Alright, now within the brain, there are many different types of neurons, but we’re going to focus only on three: serotonergic neurons that release serotonin, noradrenergic neurons that release norepinephrine, and dopaminergic neurons that release dopamine.

Each of these neurons synthesizes and stores neurotransmitters in small vesicles, so when an action potential reaches the presynaptic membrane, these vesicles fuse with the membrane, releasing neurotransmitters in the synaptic cleft.

Serotonergic neurons release serotonin, which then binds to 5-HT2 receptors, thereby increasing neural stimulation and regulating mood, feeding, and reproductive behavior.

On the other hand, noradrenergic neurons release norepinephrine, which hooks up to norepinephrine receptors (NE receptors), boosting alertness and focus.

Lastly, dopaminergic neurons release dopamine, which binds to dopamine receptors, stimulating cognitive functions, motivation, and awakeness.

As long as there’s a high enough concentration of neurotransmitters in the synaptic cleft, the postsynaptic neurons will continue to fire.

Now, each of these presynaptic neurons has small reuptake proteins, which pump the neurotransmitters from the synaptic cleft back into presynaptic neurons.

Once inside the neuron, a class of enzymes called monoamine oxidases will break down some of these neurotransmitters; monoamine oxidase A breaks down serotonin, norepinephrine, and dopamine; and monoamine oxidase B only breaks down dopamine.

The neurotransmitters that are not broken down are packaged into pre-existing vesicles, waiting to be released once more.

Now, in people with major depressive disorder, MAOIs are used to increase the levels of all the neurotransmitters related to depression.

It’s important to note that MAOI are not the first-line therapy due to their severe side effects.

Instead, selective serotonin reuptake inhibitors, or SSRIs, are used as the first-line therapy.

MAOIs can be used as the second or third line therapy, and they are especially effective in treating atypical depression.

In contrast to major depressive disorder, which is characterized by a persistent feeling of sadness, individuals with symptoms associated with atypical depression are able to improve their mood in response to positive events and circumstances.

They also experience increased appetite, weight gain, sleepiness, and fatigue.

Now, MAOIs are subdivided into two types: non-selective and selective.

Non-selective MAOIs, such as isocarboxazid, phenelzine, and tranylcypromine inhibit monoamine oxidase A and monoamine oxidase B, so serotonin, norepinephrine, and dopamine levels will increase.

These medications are also called irreversible MAOIs because they bind irreversibly to the enzymes, permanently blocking their function.

Once these enzymes are inhibited, the monoamines neurotransmitters get packed into pre-existing vesicles.

So, the next time an action potential reaches the presynaptic membrane, more neurotransmitters are released into the synaptic cleft and thus alleviating the symptoms of depression.

On the other hand, selective MAO-B inhibitor like selegiline and rasagiline will only inhibit MAO B, so they only increase the level of dopamine.

Summary

Monoamine oxidase inhibitors (MAOIs) are a class of medications used to treat depression, anxiety, and other mental health disorders. MAOIs work by blocking an enzyme called monoamine oxidase, which breaks down monoamine neurotransmitters, namely serotonin, norepinephrine, and dopamine, so they can be released again into the synapse. By blocking this enzyme, these chemicals are able to remain at higher levels in the brain, providing a beneficial effect on mood and behavior. Common side effects of MAOIs include drowsiness, dizziness, insomnia, dry mouth, and weight gain.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Neuroleptic malignant syndrome and serotonin syndrome" Thermoregulation: From Basic Neuroscience to Clinical Neurology, Part II (2018)
  5. "Mechanism of action of antidepressant medications" J Clin Psychiatry (1999)
  6. "Atypical Depression" CNS Drugs (2009)